ASX Shares Spotlight: HUB24 and Rio Tinto Performance and Valuation
March 29, 2026, 2:10 AM EDT. The Hub24 Ltd (ASX:HUB) share price has dropped 15.3% in 2025 amid strong revenue growth and a high price-to-sales ratio of 20.23x, above its 5-year average. HUB24 dominates wealth management software with platforms for financial advisers, superfunds, and accountants, winning key industry awards for service quality. Meanwhile, Rio Tinto Ltd (ASX:RIO), a global mining giant, trades 52.1% above its 52-week lows with a current dividend yield of 4.24%, below its 5-year average of 6.80%. Rio Tinto's portfolio spans aluminium, copper, diamonds, energy minerals, and iron ore. Investors use different valuation metrics for HUB's growth potential and RIO's dividend stability, highlighting varied approaches in the ASX market.
6 Key Metrics to Assess A2 Milk Company (A2M) Shares in 2025
March 29, 2026, 2:08 AM EDT. The A2 Milk Company (ASX:A2M) share price has risen 2.83% this year. Key financial indicators reveal a solid growth story: annual revenue stood at $1.67 billion with an 11.6% compound annual growth rate over three years. The firm's gross margin, a measure of core profitability, was 45.8%. Net profit hit $168 million last year, up from $81 million three years ago, reflecting a 27.6% CAGR. Financial health is strong with net debt at negative $903 million, signaling more cash than debt, and a low debt-to-equity ratio of 5.3%. Return on equity reached 12.8%, indicating efficient use of shareholder funds. These figures suggest A2M may continue on an upward trajectory in 2025, making it a stock to watch for investors interested in the dairy sector.
26-Year-Old Australian Woman Embraces Voluntary Assisted Dying Amid Chronic Illness
March 29, 2026, 12:16 AM EDT. Annaliese Holland, 26, from Adelaide, is approved for voluntary assisted dying (VAD) in South Australia due to a rare, incurable autoimmune illness. VAD allows eligible adults with terminal conditions to request medical assistance to end their life within 6 to 12 months. Despite the grim prognosis, Holland views the decision as empowering and aims to foster open dialogue about end-of-life care for young Australians. Diagnosed with Autoimmune Autonomic Ganglionopathy, she endures severe pain and debilitating symptoms daily. Holland has kept her chosen date private to protect her family, advocating for public awareness and support surrounding mortality and terminal illness.
